英文名稱 | NS-304 (Selexipag; ACT-293987) |
---|---|
中文名稱 | 賽樂(lè)西帕 | 司來(lái)帕格 |
CAS號(hào) | 475086-01-2 |
分子式 | C26H32N4O4S |
分子量 | 496.62 |
外觀 | White to yellow powder |
規(guī)格 | 庫(kù)存 | 目錄價(jià) | 會(huì)員專享價(jià) | 數(shù)量 |
---|---|---|---|---|
1 mg | 3-5days | ¥300.00 | 登錄后可見(jiàn) | |
5 mg | 3-5days | ¥500.00 | 登錄后可見(jiàn) | |
10 mg | 3-5days | ¥800.00 | 登錄后可見(jiàn) |
英文名稱 | NS-304 (Selexipag; ACT-293987) |
---|---|
中文名稱 | 賽樂(lè)西帕 | 司來(lái)帕格 |
CAS號(hào) | 475086-01-2 |
分子式 | C26H32N4O4S |
分子量 | 496.62 |
外觀 | White to yellow powder |
Selexipag, also known as ACT-293987 and NS-304, is a a first-in-class orally available selective non-prostanoid IP receptor agonist, which is currently in development by Actelion as a treatment of pulmonary arterial hypertension. Selexipag and its active metabolite, ACT-333679, are agonists at the prostacyclin receptor, which leads to vasodilation in the pulmonary circulation.